MX2017014340A - Suspension acuosa que contiene nanoparticulas de glucocorticosteroide. - Google Patents
Suspension acuosa que contiene nanoparticulas de glucocorticosteroide.Info
- Publication number
- MX2017014340A MX2017014340A MX2017014340A MX2017014340A MX2017014340A MX 2017014340 A MX2017014340 A MX 2017014340A MX 2017014340 A MX2017014340 A MX 2017014340A MX 2017014340 A MX2017014340 A MX 2017014340A MX 2017014340 A MX2017014340 A MX 2017014340A
- Authority
- MX
- Mexico
- Prior art keywords
- aqueous suspension
- nanoparticles
- suspension agent
- glucocorticosteroid
- drops
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Un objetivo es proporcionar una suspensión acuosa que contiene como componente activo un compuesto glucocorticosteroide. De modo específico, el objetivo es proporcionar una composición farmacéutica de uso práctico que contiene como componente activo un compuesto glucocorticosteroide. La presente invención es proporcionar una suspensión acuosa que contiene nanopartículas de un compuesto glucocorticosteroide y un estabilizante de dispersión, la suspensión acuosa que contiene las nanopartículas con un diámetro medio de partícula de 300 nm o menos y un diámetro de partícula D90 de 450 nm o menos, composiciones farmacéuticas para administraciones parenterales, inyecciones; gotas para los ojos o gotas para los oídos que contienen la suspensión acuosa, de modo más específico gotas para los ojos para tratar o prevenir enfermedades inflamatorias del ojo o gotas para los oídos para tratar o prevenir enfermedades inflamatorias del oído.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015095610 | 2015-05-08 | ||
PCT/JP2016/063752 WO2016181935A1 (ja) | 2015-05-08 | 2016-05-09 | グルココルチコステロイドのナノ微粒子を含有する水性懸濁液剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017014340A true MX2017014340A (es) | 2018-09-21 |
Family
ID=57248091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017014340A MX2017014340A (es) | 2015-05-08 | 2016-05-09 | Suspension acuosa que contiene nanoparticulas de glucocorticosteroide. |
Country Status (17)
Country | Link |
---|---|
US (2) | US10588913B2 (es) |
EP (1) | EP3295943B1 (es) |
JP (1) | JP6856525B2 (es) |
KR (2) | KR102390014B1 (es) |
CN (1) | CN107613985B (es) |
AU (1) | AU2016262185B2 (es) |
CA (1) | CA2985171C (es) |
ES (1) | ES2937023T3 (es) |
FI (1) | FI3295943T3 (es) |
HU (1) | HUE061418T2 (es) |
IL (1) | IL255452B (es) |
MX (1) | MX2017014340A (es) |
PL (1) | PL3295943T3 (es) |
PT (1) | PT3295943T (es) |
RU (1) | RU2747803C2 (es) |
TW (1) | TWI773641B (es) |
WO (1) | WO2016181935A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019011603A (es) * | 2017-03-26 | 2021-08-16 | Robyn Vivi Stafford | Metodo de tratamiento de las condiciones de la piel de los parpados. |
EP3641728B9 (en) * | 2017-06-23 | 2021-06-30 | Laboratorios SALVAT, S.A. | An oil-in-water nanoemulsion composition of clobetasol |
EP3691654A4 (en) | 2017-09-25 | 2021-11-24 | Surface Pharmaceuticals, Inc. | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES |
EP3962533A4 (en) * | 2019-04-30 | 2023-01-25 | The Medical College of Wisconsin, Inc. | PLATFORM FOR THROAT ADMINISTRATION AND USES THEREOF |
PT3769753T (pt) | 2019-07-23 | 2022-02-15 | Nicox Ophthalmics Inc | Processo para a preparação de suspensões aquosas oftálmicas estéreis de nanocristais de forma a de propianato de fluticasona |
CN112656760B (zh) * | 2019-09-27 | 2022-04-12 | 武汉科福新药有限责任公司 | 一种二氟泼尼酯混悬滴眼液及其制备方法 |
KR102653853B1 (ko) * | 2021-06-21 | 2024-04-01 | 가톨릭대학교 산학협력단 | 약물 전달용 나노서스펜션 및 이의 용도 |
WO2024123098A1 (ko) * | 2022-12-09 | 2024-06-13 | 가톨릭대학교 산학협력단 | 내이 특이적 약물 전달용 조성물 및 이의 용도 |
CN116077669A (zh) * | 2022-12-15 | 2023-05-09 | 中南大学湘雅医院 | 用于治疗关节痛的糖皮质激素纳米脂质载体、制法及应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747001A (en) * | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
ZA966579B (en) | 1995-08-04 | 1998-02-02 | Wakamoto Pharma Co Ltd | O/W emulsion composition for eye drops. |
JP4167463B2 (ja) * | 1997-05-14 | 2008-10-15 | 千寿製薬株式会社 | 再分散性の良い水性懸濁液剤 |
CA2289618A1 (en) | 1997-05-14 | 1998-11-19 | Shin-Ichi Yasueda | Aqueous suspension preparations with excellent redispersibility |
IT1303692B1 (it) * | 1998-11-03 | 2001-02-23 | Chiesi Farma Spa | Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione. |
US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US20040258757A1 (en) * | 2002-07-16 | 2004-12-23 | Elan Pharma International, Ltd. | Liquid dosage compositions of stable nanoparticulate active agents |
US20070178051A1 (en) | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
BRPI0717721A2 (pt) | 2006-11-28 | 2013-10-29 | Marinus Pharmaceuticals | "partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho" |
TWI405590B (zh) | 2007-04-06 | 2013-08-21 | Activus Pharma Co Ltd | 微粉碎化有機化合物粒子之製法 |
KR101534422B1 (ko) | 2008-05-14 | 2015-07-09 | 오토노미, 인코포레이티드 | 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법 |
ES2467676T3 (es) | 2008-09-19 | 2014-06-12 | Activus Pharma Co., Ltd. | Polvo de un compuesto orgánico combinado para uso médico, método para producir el mismo y suspensión del mismo |
JP2014504260A (ja) | 2010-10-15 | 2014-02-20 | グラクソ グループ リミテッド | 集合ナノ粒子状薬物製剤、その製造及び使用 |
KR20140031227A (ko) * | 2011-03-24 | 2014-03-12 | 레오 파마 에이/에스 | 지질 나노입자들 및 코르티코스테로이드 또는 비타민 d 유도체를 포함하는 조성물 |
BR112014028431B1 (pt) * | 2012-05-11 | 2022-01-11 | Activus Pharma Co., Ltd | Nanopó de composto orgânico, método para produzir o mesmo e suspensão |
CN104884049A (zh) | 2012-11-08 | 2015-09-02 | 克莱尔塞德生物医学股份有限公司 | 用于在人类受试者中治疗眼部疾病的方法和装置 |
-
2016
- 2016-05-06 TW TW105114243A patent/TWI773641B/zh active
- 2016-05-09 US US15/571,986 patent/US10588913B2/en active Active
- 2016-05-09 JP JP2017517933A patent/JP6856525B2/ja active Active
- 2016-05-09 EP EP16792660.9A patent/EP3295943B1/en active Active
- 2016-05-09 KR KR1020217018618A patent/KR102390014B1/ko active IP Right Grant
- 2016-05-09 RU RU2017142694A patent/RU2747803C2/ru active
- 2016-05-09 FI FIEP16792660.9T patent/FI3295943T3/fi active
- 2016-05-09 CN CN201680026845.5A patent/CN107613985B/zh active Active
- 2016-05-09 AU AU2016262185A patent/AU2016262185B2/en active Active
- 2016-05-09 MX MX2017014340A patent/MX2017014340A/es unknown
- 2016-05-09 KR KR1020177033330A patent/KR102268710B1/ko active IP Right Grant
- 2016-05-09 PT PT167926609T patent/PT3295943T/pt unknown
- 2016-05-09 CA CA2985171A patent/CA2985171C/en active Active
- 2016-05-09 IL IL255452A patent/IL255452B/en unknown
- 2016-05-09 HU HUE16792660A patent/HUE061418T2/hu unknown
- 2016-05-09 WO PCT/JP2016/063752 patent/WO2016181935A1/ja active Application Filing
- 2016-05-09 PL PL16792660.9T patent/PL3295943T3/pl unknown
- 2016-05-09 ES ES16792660T patent/ES2937023T3/es active Active
-
2019
- 2019-12-31 US US16/732,173 patent/US11376262B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
HUE061418T2 (hu) | 2023-06-28 |
CN107613985B (zh) | 2021-05-25 |
TW201701882A (zh) | 2017-01-16 |
EP3295943B1 (en) | 2022-11-30 |
CA2985171C (en) | 2021-11-02 |
IL255452B (en) | 2022-08-01 |
CN107613985A (zh) | 2018-01-19 |
RU2017142694A3 (es) | 2019-11-11 |
US11376262B2 (en) | 2022-07-05 |
US20180117064A1 (en) | 2018-05-03 |
BR112017024000A2 (pt) | 2018-07-17 |
FI3295943T3 (fi) | 2023-03-03 |
US20200129526A1 (en) | 2020-04-30 |
PL3295943T3 (pl) | 2023-05-08 |
EP3295943A1 (en) | 2018-03-21 |
AU2016262185A1 (en) | 2017-12-21 |
TWI773641B (zh) | 2022-08-11 |
EP3295943A4 (en) | 2019-01-02 |
JP6856525B2 (ja) | 2021-04-07 |
US10588913B2 (en) | 2020-03-17 |
KR20210076202A (ko) | 2021-06-23 |
JPWO2016181935A1 (ja) | 2018-02-22 |
WO2016181935A1 (ja) | 2016-11-17 |
CA2985171A1 (en) | 2016-11-17 |
PT3295943T (pt) | 2023-02-02 |
IL255452A (en) | 2018-01-31 |
KR102390014B1 (ko) | 2022-04-22 |
KR102268710B1 (ko) | 2021-06-23 |
RU2747803C2 (ru) | 2021-05-14 |
RU2017142694A (ru) | 2019-06-10 |
KR20180004164A (ko) | 2018-01-10 |
AU2016262185B2 (en) | 2021-05-13 |
ES2937023T3 (es) | 2023-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017014340A (es) | Suspension acuosa que contiene nanoparticulas de glucocorticosteroide. | |
PH12019550088A1 (en) | Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery | |
MX2021007794A (es) | Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones. | |
MX2018004376A (es) | Formulaciones inyectables de neuroesteroides que contienen nanoparticulas. | |
PH12015502587B1 (en) | Ophthalmic nanoemulsion composition containing cyclosporine and method for preparing same | |
PH12018500905A1 (en) | Aggregating microparticles for medical therapy | |
PH12016501794A1 (en) | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | |
AU2015336400A8 (en) | Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof | |
MX2016005764A (es) | Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos. | |
PE20150997A1 (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos para realizarlas y usarlas | |
SA515361055B1 (ar) | نواتج تكتل قابلة للاستنشاق من جسيمات حاملة مسامية وعقار بحجم الميكرون | |
WO2013042125A3 (en) | Nano delivery systems for sirna | |
MX2011012196A (es) | Composiciones y metodos para el suministro de farmaco. | |
WO2011107755A3 (en) | Immediate/delayed drug delivery | |
MX2018010788A (es) | Composicion oftalmologica. | |
PH12019501902A1 (en) | Ocular formulations for drug-delivery to the posterior segment of the eye | |
WO2015152693A3 (ko) | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 | |
MX2015010083A (es) | Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos. | |
MX2018000637A (es) | Nanocápsula para la administración de un compuesto lipófilo y proceso de preparación de la misma. | |
MX2017009699A (es) | Composicion de suspension oftalmica. | |
MX2015011280A (es) | Moduladores de ship1 y metodos relacionados con los mismos. | |
MY155938A (en) | Oral pharmaceutical composition | |
MX2017015250A (es) | Formacion de nanoparticulas de ciclosporina a/ciclodextrina. | |
MX2019010852A (es) | Nanoparticulas a base de lipidos con estabilidad mejorada. | |
CA3010981A1 (en) | Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers |